PROCR and cancer: Flow cytometry analysis of CD56 and CD201 expression upon shRNA treatment in these cells showed insignificant differences (Figure 4P and Q, Figure 4—figure supplements 2 and 3), demonstrating that the expression of cancer stem cell markers was irreversible.